Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Bio    DIM   FR0013154002

Real-time Quote. Real-time Tradegate - 07/29 09:59:54 pm
63.442 EUR   -1.29%
07/20SARTORIUS STEDI : half-yearly earnings release
07/07 SARTORIUS STEDI : acquires U.S. start-up kSep Systems; Transaction t..
06/16 SARTORIUS STEDI : launches innovative ambr 250 modular bioreactor sy..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SARTORIUS STED BIO : Sartorius Stedim Biotech and c-LEcta sign sales agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 01:05pm CEST
SSB sells and distributes Serratia marcescens nuclease worldwide | Perfect addition to SSB´s purification product portfolio

Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, and the biotechnology specialist c LEcta, announce the signing of a worldwide sales and distribution agreement for c LEcta's proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name "Denarase" through all regular Sartorius Stedim Biotech sales channels.

Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies. The company c-LEcta has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins. As a result, this new technology enables the highest purity and quality nuclease to be produced.

"This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry."

Dr. Marc Struhalla, Managing Director of c-LEcta comments, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialization of our product."

About c-LEcta GmbH

c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SARTORIUS STEDIM BIO
07/20SARTORIUS STEDIM BIOTECH SA : half-yearly earnings release
07/07 SARTORIUS STEDIM BIOTECH : acquires U.S. start-up kSep Systems; Transaction to e..
06/16 SARTORIUS STEDIM BIO : Researchers Submit Patent Application, "Fluid Connector w..
06/16 SARTORIUS STEDIM BIOTECH : launches innovative ambr 250 modular bioreactor syste..
06/16 SARTORIUS STEDIM BIO : New Sartorius Stedim BioOutsource Microsite Goes Live; Ce..
06/13 SARTORIUS STEDIM BIOTECH : Presents Virosart Media
06/09 SARTORIUS STEDIM BIO : "Fluid Connector with Clamp and Protection" in Patent App..
06/01 SARTORIUS STEDIM BIO : WuXi Biologics and Sartorius Stedim Biotech Open Joint La..
05/06 SARTORIUS STEDIM BIOTECH SA : SPLIT: 6 of 1
04/13 SARTORIUS STEDIM BIO : ex-dividend day for annual dividend
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
07/28DJZIMMER BIOMET : Boosts Bottom End of Earnings Forecast as Loss Narrows
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJAlere Faces Criminal Probe Over Medicare, Medicaid Billing
07/26DJBAXTER : Results Boosted by Growth in Hospital Products Segment
07/25DJBAXTER : CFOs Turn to Consultants as Challenges Mount
More sector news : Medical Equipment, Supplies & Distribution - NEC
Advertisement
Financials (€)
Sales 2016 1 034 M
EBIT 2016 238 M
Net income 2016 162 M
Debt 2016 46,8 M
Yield 2016 0,60%
P/E ratio 2016 38,31
P/E ratio 2017 33,49
EV / Sales 2016 5,78x
EV / Sales 2017 5,14x
Capitalization 5 924 M
More Financials
Chart SARTORIUS STEDIM BIO
Duration : Period :
Sartorius Stedim Bio Technical Analysis Chart | DIM | FR0013154002 | 4-Traders
Full-screen chart
Technical analysis trends SARTORIUS STEDIM BIO
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 68,2 €
Spread / Average Target 6,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive Director & Executive VP-Operations
Oscar-Werner Reif Executive Director, EVP-Research & Development
Reinhard Vogt Executive Director, EVP-Marketing & Sales Services
Liliane de Lassus Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIO11.90%6 564
MEDTRONIC PLC13.65%121 927
BAXTER INTERNATIONAL I..26.40%26 630
ZIMMER BIOMET HOLDINGS..24.25%25 453
C R BARD INC18.38%16 472
TERUMO CORP19.54%16 383
More Results